Boryung (KRX:003850) has concluded a seven-year export supply and distribution agreement with China's Yifan Pharmaceutical (SHE:002019) for Taxotere, valued at 383.65 billion won.
Yifan Pharmaceutical, a Shenzhen-listed oncology-focused company with 2025 consolidated revenue of 1.06 trillion won, is obligated to purchase at least 90% of the contracted volume annually or compensate the company in cash for any shortfall.
The contract period runs from Sept. 21, 2026 to Sept. 20, 2033, though the end date may vary depending on when the marketing authorization transfer in China is completed.
The agreement carries no deposit or advance payment requirement, and the end date may be adjusted by mutual consent between the two parties.